S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Forecast, Price & News

$0.62
+0.06 (+10.32%)
(As of 05:11 PM ET)
Compare
Today's Range
$0.57
$0.63
50-Day Range
$0.56
$1.23
52-Week Range
$0.54
$14.18
Volume
42,077 shs
Average Volume
108,557 shs
Market Capitalization
$1.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GLMD stock logo

About Galmed Pharmaceuticals (NASDAQ:GLMD) Stock

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GLMD Price History

GLMD Stock News Headlines

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
GLMD Galmed Pharmaceuticals Ltd.
See More Headlines
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Company Calendar

Last Earnings
8/09/2023
Today
9/29/2023
Next Earnings (Estimated)
11/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLMD
Employees
4
Year Founded
N/A

Profitability

Net Income
$-17,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.98 per share

Miscellaneous

Free Float
1,347,000
Market Cap
$1.01 million
Optionable
Optionable
Beta
0.94
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Allen Baharaff (Age 58)
    Co-Founder, Pres, CEO & Chairman
    Comp: $803.5k
  • Mr. Doron Cohen (Age 56)
    Chief Financial Officer
    Comp: $175.33k
  • Mr. Guy Nehemya (Age 38)
    COO & Data Protection Officer
    Comp: $235.56k
  • Mr. Yohai Stenzler CPA (Age 40)
    Chief Accounting Officer
    Comp: $239.48k
  • Dr. Liat Hayardeny (Age 56)
    Chief Scientific Officer
    Comp: $125.24k
  • Ms. Yael Hollander (Age 40)
    VP of Legal Affairs & Strategy
  • Ms. Shani Ganon
    HR Mang.
  • Dr. Tali Gorfine (Age 53)
    Medical Consultant













GLMD Stock - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLMD shares.
View GLMD analyst ratings
or view top-rated stocks.

How have GLMD shares performed in 2023?

Galmed Pharmaceuticals' stock was trading at $7.50 on January 1st, 2023. Since then, GLMD stock has decreased by 92.0% and is now trading at $0.6024.
View the best growth stocks for 2023 here
.

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023.
View our GLMD earnings forecast
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter.

When did Galmed Pharmaceuticals' stock split?

Galmed Pharmaceuticals's stock reverse split on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $0.60.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $1.01 million. The biopharmaceutical company earns $-17,870,000.00 in net income (profit) each year or ($6.6877) on an earnings per share basis.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.

This page (NASDAQ:GLMD) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -